SPOTLIGHT -
Raising Awareness About NMOSD
Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.
Critical Aspects of NMOSD Clinical Care: Brian G. Weinshenker, MD
The professor of neurology at the Mayo Clinic College of Medicine highlighted the importance of the diagnostic process and implementing an early treatment regimen for patients with NMOSD.
Promising Biomarkers for NMOSD Activity: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed which biomarkers have shown the most relevancy in NMOSD and which deserve more attention.
Future Directions of NMOSD Research: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed several areas within the neuromyelitis optica spectrum disorder that are of interest for ongoing and new research efforts.
NMOSD Treatment Landscape and Pipeline: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed the 3 currently FDA-approved agents for NMOSD and other agents currently within the clinical pipeline.
Unsolved Questions Regarding NMOSD Disease Progression: Brian G. Weinshenker, MD
The professor of neurology at Mayo Clinic College of Medicine discussed lesser-known facets of NMOSD and how the disease evolves over time.
Biggest Advances in NMOSD Management, Diagnosis: Brian G. Weinshenker, MD
The professor of neurology at the Mayo Clinic College of Medicine detailed the strides made in recognizing NMOSD as its own disease, along with specific biomarkers that identify it.
Understanding Infection Risk With Multiple Sclerosis DMTs: Brian G. Weinshenker, MD
The professor of neurology at the Mayo Clinic College of Medicine discussed the need for evaluating infection risk of disease-modifying therapies amid a growing MS treatment landscape.
